LRRC44 activators encompass a diverse array of chemical compounds that enhance its activity through various biochemical pathways. Sildenafil, by inhibiting phosphodiesterase-5, elevates cGMP levels, which can enhance LRRC44's activity in cGMP-mediated signaling. Similarly, Forskolin, through activation of adenylate cyclase, increases cAMP levels, potentially enhancing LRRC44's role in cAMP-dependent pathways. In contrast, Y-27632 and LY294002 target the RhoA/ROCK and PI3K/Akt pathways, respectively, indirectly influencing LRRC44 activity in processes where these pathways intersect with LRRC44's functional role. The modulation of calcium signaling is another avenue through which LRRC44 activity is influenced; compounds like U73122, Ionomycin, and BAPTA-AM, by altering intracellular calcium levels or calcium signaling dynamics, can enhance LRRC44 activity in calcium-dependent processes. The role of phosphorylation state changes in LRRC44's activity is highlighted by compounds like Okadaic Acid, which inhibits protein phosphatases, and D4476, a casein kinase 1 inhibitor, suggesting LRRC44's involvement in pathways regulated by phosphorylation.
Furthermore, the impact of specific kinase signaling pathways on LRRC44 is evident in the use of compounds like SB203580 and PD98059, which inhibit p38 MAPK and MEK, respectively. By modulating these pathways, these inhibitors may enhance LRRC44 activity in cellular processes downstream of MAPK signaling. KN-93, a CaMKII inhibitor, also underscores LRRC44's potential involvement in pathways regulated by CaMKII signaling. The collective action of these compounds highlights LRRC44's role in a complex network of signaling pathways, with its activity being modifiable through diverse pharmacological interventions that target various aspects of cellular signaling. This intricate modulation of LRRC44 by different activators through distinct pathways underlines the protein's versatile role in cellular physiology and its potential as a target for pharmacological manipulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632, a ROCK inhibitor, disrupts the RhoA/ROCK pathway. By inhibiting ROCK, Y-27632 may indirectly enhance LRRC44 activity, particularly in cellular processes where RhoA/ROCK signaling intersects with LRRC44's functional role. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin, a calcium ionophore, increases intracellular calcium levels, potentially enhancing LRRC44 activity in pathways where calcium signaling is a critical regulator and LRRC44 plays a role. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, alters PI3K/Akt signaling. This modulation can lead to enhanced LRRC44 activity in pathways where LRRC44 is indirectly regulated by PI3K/Akt signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a p38 MAPK inhibitor, modifies the MAPK signaling pathway. This alteration can lead to the enhancement of LRRC44 activity in cellular processes where LRRC44 is involved downstream of MAPK signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, an inhibitor of MEK, which is upstream of ERK, can indirectly enhance LRRC44 activity by modulating signaling pathways where LRRC44 functions downstream of the ERK pathway. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic Acid, a protein phosphatase inhibitor, influences phosphorylation states within cells. This can lead to enhanced LRRC44 activity in pathways where LRRC44 is regulated by phosphorylation events. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $458.00 | 61 | |
BAPTA-AM, a calcium chelator, can indirectly enhance LRRC44 activity by modulating calcium signaling pathways where LRRC44 is a downstream effector. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
D4476, a casein kinase 1 inhibitor, may enhance LRRC44 activity by influencing pathways where LRRC44 is regulated downstream of casein kinase 1. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
KN-93, a CaMKII inhibitor, can indirectly enhance LRRC44 activity by affecting pathways where LRRC44 is involved downstream of CaMKII signaling. | ||||||